Previous 10 | Next 10 |
2023-09-24 22:33:00 ET Summary Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene...
2023-09-22 14:48:41 ET Summary Dimensional International Value ETF is an actively managed fund picking value stocks in developed countries except the U.S. It is overweight in financials, but it is well diversified across countries and holdings. Valuation ratios, growth metrics...
2023-09-19 06:58:00 ET More on BeiGene, Novartis, etc. Sales Success Comes With Side Effects For Drug Maker BeiGene Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis shareholders approve 100...
2023-09-18 15:20:36 ET Summary Initiation of the pivotal OPERA-01 study, using palazestrant for the treatment of 2nd-line/3rd-line HR+/HER2- metastatic breast cancer patients, expected in Q4 of 2023. Monotherapy results from the phase 2 study, using palazestrant for the treatment ...
2023-09-18 15:05:48 ET More on Merck Republicans say Medicare drug negotiations will mean fewer new meds Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump? Despite The One-Time Charge, Merck Is Still A Buy Gilead says Trodelvy w...
2023-09-17 18:42:40 ET The rivalry between Acelyrin ( NASDAQ: SLRN ) and MoonLake Immunotherapeutics ( NASDAQ: MLTX ) is heating up, with both expected to release potentially market-moving data in the next few months for their respective drugs to treat psoriatic arthritis, a...
2023-09-16 08:26:36 ET Summary The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. IXJ: a global alternative to ...
2023-09-15 17:37:08 ET More on Novartis Seeking Alpha’s Quant Rating on Novartis Historical earnings data for Novartis Dividend scorecard for Novartis Financial information for Novartis Novartis: Q2 Beats Expectations, But Still Pricey ...
2023-09-15 11:05:45 ET More on Lilly, Ascendis, and Novartis Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Sandoz to commercialize biosimilar to J&J blockbuster drug ...
2023-09-13 10:00:00 ET Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown that a high yield is only as secure as the business that supports it. M...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...